AVP and major depressive disorder: Our findings provide first evidence in humans that the AVP surrogate marker CoP might represent a novel, easily accessible and clinically applicable biomarker of excellent predictive properties, which can correctly identify treatment response in MDD patients through a single measurement based on a cut-off level.